Reconstituting electrical conduction in soft tissue: the path to replace the ablationist

Europace. 2021 Dec 7;23(12):1892-1902. doi: 10.1093/europace/euab187.

Abstract

Cardiac arrhythmias are a leading cause of morbidity and mortality in the developed world. A common mechanism underlying many of these arrhythmias is re-entry, which may occur when native conduction pathways are disrupted, often by myocardial infarction. Presently, re-entrant arrhythmias are most commonly treated with antiarrhythmic drugs and myocardial ablation, although both treatment methods are associated with adverse side effects and limited efficacy. In recent years, significant advancements in the field of biomaterials science have spurred increased interest in the development of novel therapies that enable restoration of native conduction in damaged or diseased myocardium. In this review, we assess the current landscape of materials-based approaches to eliminating re-entrant arrhythmias. These approaches potentially pave the way for the eventual replacement of myocardial ablation as a preferred therapy for such pathologies.

Keywords: Arrhythmias; Atrial fibrillation; Cardiac conduction defect; Catheter ablation; Radiofrequency ablation; Re-entrant curcuit.

Publication types

  • Review

MeSH terms

  • Anti-Arrhythmia Agents
  • Arrhythmias, Cardiac / diagnosis
  • Arrhythmias, Cardiac / surgery
  • Catheter Ablation* / adverse effects
  • Heart Rate
  • Humans
  • Myocardial Infarction* / complications

Substances

  • Anti-Arrhythmia Agents